Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK on NicoWater

This article was originally published in The Tan Sheet

Executive Summary

Nicorette and Nicoderm marketer "urges FDA to advise QT5 that it must immediately cease distribution and marketing" of its nicotine-containing beverage NicoWater as an OTC homeopathic product in recent comments. Claims in radio advertising and labeling that NicoWater "relieves the symptoms of tobacco cravings" render the product an unapproved new drug, the letter states. GSK also laments that FDA's failure to take action against the product has allowed QT5 to arrange for NicoWater to be sold through Rite Aid and Eckerd stores, and made it easier for consumers to purchase the product over the Internet. The comments follow a citizen petition objecting to the sale of NicoWater as an OTC homeopathic product, filed by the NRT marketer in March (1"The Tan Sheet" April 7, 2003, p. 7)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel